Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis.

[1]  L. Brown,et al.  Osteopontin at the Tumor/Host Interface , 1995, Annals of the New York Academy of Sciences.

[2]  G. Rodan.  Osteopontin Overview , 1995, Annals of the New York Academy of Sciences.

[3]  D. Cheresh,et al.  An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. , 1995, Journal of cell science.

[4]  H. Dvorak,et al.  Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. , 1995, The Journal of investigative dermatology.

[5]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[6]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[7]  H. Dvorak,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. , 1995, The Journal of investigative dermatology.

[8]  R. Warren,et al.  Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.

[9]  E. Manseau,et al.  Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. , 1995, Journal of Immunology.

[10]  Kenneth M. Yamada,et al.  Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function , 1995, Science.

[11]  Z. Khalkhali‐Ellis,et al.  Enhanced expression of alpha v integrin subunit and osteopontin during differentiation of HL-60 cells along the monocytic pathway. , 1995, Experimental cell research.

[12]  R. Ross,et al.  The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. , 1995, The Journal of clinical investigation.

[13]  Lois E. H. Smith,et al.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[15]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[16]  S M Schwartz,et al.  Macrophages express osteopontin during repair of myocardial necrosis. , 1994, The American journal of pathology.

[17]  R. Klemke,et al.  Receptor tyrosine kinase signaling required for integrin alpha v beta 5- directed cell motility but not adhesion on vitronectin , 1994, The Journal of cell biology.

[18]  E. Manseau,et al.  Osteopontin expression and distribution in human carcinomas. , 1994, The American journal of pathology.

[19]  E. Brown,et al.  Basic Fibroblast Growth Factor Increases Expression of the αvβ3 Integrin Complex on Human Microvascular Endothelial Cells , 1994 .

[20]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[21]  J. Moringlane,et al.  Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? , 1994, Neurosurgery.

[22]  E. Keshet,et al.  Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. , 1994, Cardiovascular research.

[23]  N. Olsen,et al.  Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.

[24]  Timothy A. Springer,et al.  The dynamic regulation of integrin adhesiveness , 1994, Current Biology.

[25]  L. Water,et al.  Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. , 1994, Molecular biology of the cell.

[26]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[27]  M. Schwartz,et al.  Alpha v integrins mediate the rise in intracellular calcium in endothelial cells on fibronectin even though they play a minor role in adhesion. , 1994 .

[28]  A. Mukherjee,et al.  Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. , 1994, Journal of biochemistry.

[29]  D. G. Chalupowicz,et al.  Transglutaminase-mediated processing of fibronectin by endothelial cell monolayers. , 1994, Biochemistry.

[30]  S. Schwartz,et al.  Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.

[31]  E. Brogi,et al.  Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.

[32]  D. Denhardt,et al.  Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[34]  E. Bendixen,et al.  Transglutaminases catalyze cross-linking of plasminogen to fibronectin and human endothelial cells. , 1993, The Journal of biological chemistry.

[35]  L. Williams,et al.  Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[37]  D. Rifkin,et al.  Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. , 1993, Molecular biology of the cell.

[38]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Bourdon,et al.  Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. , 1993, Journal of cell science.

[40]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. , 1993, Cancer research.

[41]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[42]  E. Oldfield,et al.  Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. , 1993, The American journal of physiology.

[43]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[44]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[45]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[46]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[47]  B. Spiegelman,et al.  Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. , 1992, The Journal of biological chemistry.

[48]  D. Leavesley,et al.  Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen , 1992, The Journal of cell biology.

[49]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[50]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[51]  George E. Davis,et al.  Affinity of integrins for damaged extracellular matrix: αvβ3 binds to denatured collagen type I through RGD sites , 1992 .

[52]  N. Ferrara,et al.  Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.

[53]  L. Orci,et al.  Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. , 1991, Biochemical and biophysical research communications.

[54]  C. W. Prince,et al.  Osteopontin, a substrate for transglutaminase and factor XIII activity. , 1991, Biochemical and biophysical research communications.

[55]  M. Detmar,et al.  Effects of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis. , 1990, The Journal of investigative dermatology.

[56]  C. Semenkovich,et al.  A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. , 1990, Biochemistry.

[57]  W. T. Chen,et al.  Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. , 1990, Cancer research.

[58]  D. Connolly,et al.  Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. , 1990, Cancer research.

[59]  D. Connolly,et al.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.

[60]  D. Gospodarowicz,et al.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[61]  C. Perruzzi,et al.  Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. , 1989, Anticancer research.

[62]  W. T. Chen,et al.  Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization , 1989, The Journal of cell biology.

[63]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[64]  D. Tenen,et al.  Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. , 1989, Biochimica et biophysica acta.

[65]  P. Barr,et al.  The cDNA and derived amino acid sequence for human osteopontin. , 1989, Nucleic acids research.

[66]  D. Tenen,et al.  Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. , 1988, Cancer research.

[67]  D. Cheresh,et al.  Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. , 1987, The Journal of biological chemistry.

[68]  M. Poncz,et al.  Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. , 1987, Biochemistry.

[69]  S. Lo,et al.  Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". , 1987, The Journal of biological chemistry.

[70]  H. Dvorak,et al.  Regulation of extravascular coagulation by microvascular permeability. , 1985, Science.

[71]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[72]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[73]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.

[74]  D. Ruiter,et al.  Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. , 1995, The American journal of pathology.

[75]  D. Cheresh,et al.  An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization , 1995 .

[76]  R. Klemke,et al.  Receptor Tyrosine Kinase Signaling Required for Integrin c v/35-directed Cell Motility but Not Adhesion on Vitronectin , 1994 .

[77]  J. Folkman,et al.  Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy , 1995 .

[78]  W. Reinhold,et al.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.

[79]  M. Bourdon,et al.  Endothelial cell attachment and spreading on human tenascin is mediated by 2 1 and V 3 integrins , 2022 .